{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:53Z","timestamp":1792822013643,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T00:00:00Z","timestamp":1374192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40258-013-0047-8","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T09:58:30Z","timestamp":1374141510000},"page":"485-497","source":"Crossref","is-referenced-by-count":68,"title":["Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US"],"prefix":"10.1007","volume":"11","author":[{"given":"Anju","family":"Parthan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Yurgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joice","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema N.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,19]]},"reference":[{"key":"47_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"National Institutes of Health (NIH) Consensus Development Panel","year":"2001","unstructured":"National Institutes of Health (NIH) Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785\u201395.","journal-title":"JAMA"},{"key":"47_CR2","unstructured":"Kanis JA. WHO Technical Report 2007. University of Sheffield, UK."},{"issue":"9","key":"47_CR3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","volume":"7","author":"LJ Melton III","year":"1992","unstructured":"Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res. 1992;7(9):1005\u201310.","journal-title":"J Bone Miner Res"},{"key":"47_CR4","volume-title":"Bone health and osteoporosis: a report of the Surgeon General","author":"US Department of Health and Human Services","year":"2004","unstructured":"US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Office of the Surgeon General; 2004."},{"issue":"4 Suppl 1","key":"47_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2005.12.017","volume":"119","author":"M Gass","year":"2006","unstructured":"Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119(4 Suppl 1):S3\u201311.","journal-title":"Am J Med"},{"key":"47_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-004-1813-0","volume":"16","author":"PD Delmas","year":"2005","unstructured":"Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int. 2005;16:1\u20135.","journal-title":"Osteoporos Int"},{"key":"47_CR7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. NEJM. 2005;353:487\u201397.","journal-title":"NEJM"},{"key":"47_CR8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645\u201352.","journal-title":"Osteoporos Int"},{"issue":"8","key":"47_CR9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM. 2009;361(8):756\u201365.","journal-title":"NEJM"},{"issue":"1","key":"47_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang E-T, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317\u201326.","journal-title":"Osteoporos Int"},{"key":"47_CR11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B Jonsson","year":"2011","unstructured":"Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967\u201382.","journal-title":"Osteoporos Int"},{"issue":"1","key":"47_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.03.009","volume":"47","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone. 2010;47(1):34\u201340.","journal-title":"Bone"},{"issue":"10","key":"47_CR13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29(10):895\u2013911.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"47_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","volume":"29","author":"G Scotland","year":"2011","unstructured":"Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"47_CR15","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727\u201336.","journal-title":"J Clin Endocrinol Metab"},{"key":"47_CR16","unstructured":"Denosumab (Prolia) Prescribing Information, June 2010I."},{"key":"47_CR17","unstructured":"National Institute for Health and Clinical Excellence (UK). Systematic reviews of clinical effectiveness prepared for the guideline \u2018Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk\u2019. National Collaborating Centre for Nursing and Supportive Care, September 2008. http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&o=42362 ."},{"key":"47_CR18","doi-asserted-by":"crossref","unstructured":"Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972\u201380.","DOI":"10.1210\/jc.2010-1502"},{"issue":"1","key":"47_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s001980050113","volume":"9","author":"LJ Melton III","year":"1999","unstructured":"Melton LJ III, Crowson CS, O\u2019Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999;9(1):29\u201337.","journal-title":"Osteoporos Int"},{"key":"47_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01623271","volume":"3","author":"LJ Melton III","year":"1993","unstructured":"Melton LJ III, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113\u20139.","journal-title":"Osteoporos Int"},{"issue":"2","key":"47_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","volume":"7","author":"C Cooper","year":"1992","unstructured":"Cooper C, Atkinson EJ, O\u2019Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989. J Bone Miner Res. 1992;7(2):221\u20137.","journal-title":"J Bone Miner Res"},{"key":"47_CR22","unstructured":"http:\/\/www.Mortality.org . US Life Tables\u00a02007."},{"issue":"2","key":"47_CR23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15(2):108\u201312.","journal-title":"Osteoporos Int"},{"key":"47_CR24","first-page":"260","volume":"319","author":"G Poor","year":"1995","unstructured":"Poor G, Atkinson EJ, O\u2019Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clin Orthop. 1995;319:260\u20135.","journal-title":"Clin Orthop"},{"key":"47_CR25","volume-title":"Excess mortality after vertebral fracture","author":"J Kanis","year":"2002","unstructured":"Kanis J, et al. Excess mortality after vertebral fracture. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases; 2002."},{"issue":"6","key":"47_CR26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","volume":"105","author":"MJ Parker","year":"1991","unstructured":"Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health. 1991;105(6):443\u20136.","journal-title":"Public Health"},{"issue":"5","key":"47_CR27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone. 2003;32(5):468\u201373.","journal-title":"Bone"},{"key":"47_CR28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Int Med. 2010;152:380\u201390.","journal-title":"Ann Int Med"},{"issue":"6","key":"47_CR29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-009-0844-y","volume":"20","author":"T Peasgood","year":"2009","unstructured":"Peasgood T, Herrmann K, Kanis JA, et al. An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853\u201368.","journal-title":"Osteoporos Int"},{"issue":"17","key":"47_CR30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200422170-00005","volume":"22","author":"F Borgstrom","year":"2004","unstructured":"Borgstrom F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmocoeconomics. 2004;22(17):1153\u201365.","journal-title":"Pharmocoeconomics"},{"issue":"7","key":"47_CR31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","volume":"15","author":"A Oleksik","year":"2000","unstructured":"Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15(7):1384\u201392.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"47_CR32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","volume":"12","author":"AN Tosteson","year":"2001","unstructured":"Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001;12(12):1042\u20139.","journal-title":"Osteoporos Int"},{"issue":"11","key":"47_CR33","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N","volume":"44","author":"SL Silverman","year":"2001","unstructured":"Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum. 2001;44(11):2611\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"47_CR34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s001980050178","volume":"9","author":"SE Hall","year":"1999","unstructured":"Hall SE, Criddle RA, Comito TL, Prince RL. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int. 1999;9(6):508\u201315.","journal-title":"Osteoporos Int"},{"issue":"12","key":"47_CR35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int. 2006;17(12):781\u201393.","journal-title":"Osteoporos Int"},{"issue":"4","key":"47_CR36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26(4):391\u2013400.","journal-title":"Med Decis Mak"},{"key":"47_CR37","unstructured":"Marketscan Database Analysis. Data on file-Amgen 2010."},{"key":"47_CR38","unstructured":"National Hospital Discharge Survey (NHDS) Data 2006\u2014National Center for Health Statistics: Centers for Disease Control and Prevention."},{"issue":"10","key":"47_CR39","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/aje\/kwp266","volume":"170","author":"SE Bentler","year":"2009","unstructured":"Bentler SE, Liu L, ObrizanM, et al. The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epi. 2009;170(10):1290\u20139.","journal-title":"Am J Epi"},{"key":"47_CR40","unstructured":"Stevenson M, Davis S. Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, edifronate and teriparatide. 2006. http:\/\/www.nice.org.uk\/page.aspx?0=370643 . Accessed 12 May 2008."},{"key":"47_CR41","unstructured":"Healthcare Costs & Utilization Project Database based on US Nationwide Inpatient Sample. http:\/\/hcupnet.ahrq.gov\/ ."},{"key":"47_CR42","unstructured":"Denosumab Clinical Study Report, Nov 2008."},{"issue":"6","key":"47_CR43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","volume":"30","author":"WK Redekop","year":"2004","unstructured":"Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30(6):549\u201356.","journal-title":"Diabetes Metab"},{"issue":"6","key":"47_CR44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed in a managed care population. Bone. 2006;38(6):922\u20138.","journal-title":"Bone"},{"issue":"20","key":"47_CR45","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"D Solomon","year":"2005","unstructured":"Solomon D, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch inter Med. 2005;165(20):2414\u20139.","journal-title":"Arch inter Med"},{"issue":"1","key":"47_CR46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Reginster JY, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23(1):213\u201321.","journal-title":"Osteoporos Int"},{"key":"47_CR47","unstructured":"Boonen S, McClung M, Minisola S, et al. 2009. Effect of denosumab on the incidence of hip, new vertebral and nonvertebral fractures over 3\u00a0years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM study. J Bone Miner Res 24(Suppl 1). http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=da35831c-de93-4607-8b12-b7fcaf42f45d . Accessed March 23 2012."},{"issue":"5","key":"47_CR48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bone.2008.12.003","volume":"44","author":"CA Inderjeeth","year":"2009","unstructured":"Inderjeeth CA, Foo ACH, Lai MMY, et al. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone. 2009;44(5):744\u201351.","journal-title":"Bone"},{"key":"47_CR49","doi-asserted-by":"crossref","unstructured":"McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal ostoeoporosis. J Bone Miner Res. 2011. doi: 10.1002\/jbmr.536 .","DOI":"10.1002\/jbmr.536"},{"issue":"5","key":"47_CR50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"47_CR51","first-page":"1","volume":"7","author":"ES Meadows","year":"2007","unstructured":"Meadows ES, Klein R, Rousculp MD, et al. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health. 2007;7(6):1\u20139.","journal-title":"BMC Womens Health"},{"key":"47_CR52","unstructured":"National Osteoporosis Foundation. Osteoporos Int. 1998; (Suppl 4)S7\u2013S80."},{"key":"47_CR53","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","volume":"166","author":"H Liu","year":"2006","unstructured":"Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166:1209\u201317.","journal-title":"Arch Intern Med"},{"key":"47_CR54","unstructured":"Physician\u2019s Fee and Coding Guide 2012. MAG Mutual Healthcare Solutions, 2011."},{"key":"47_CR55","unstructured":"Drug Topics Red Book. Montvale: Thomson Healthcare; 2010."},{"key":"47_CR56","unstructured":"AnalySource 2011. WAC Pricing, November 1, 2011."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0047-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0047-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:38Z","timestamp":1559503718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0047-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,19]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0047-8","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,19]]}}}